Acquisition by Tomasello Shawn of 17000 shares of Gamida Cell subject to Rule 16b-3
GMDADelisted Stock | USD 1.40 0.09 6.04% |
About 61% of Gamida Cell's investor base is looking to short. The analysis of current outlook of investing in Gamida Cell suggests that many traders are alarmed regarding Gamida Cell's prospects. The current market sentiment, together with Gamida Cell's historical and current headlines, can help investors time the market. In addition, many technical investors use Gamida Cell stock news signals to limit their universe of possible portfolio assets.
Gamida |
Filed transaction by Gamida Cell Ltd director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Gamida Cell Fundamental Analysis
We analyze Gamida Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gamida Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gamida Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Gamida Cell is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Gamida Cell Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gamida Cell stock to make a market-neutral strategy. Peer analysis of Gamida Cell could also be used in its relative valuation, which is a method of valuing Gamida Cell by comparing valuation metrics with similar companies.
Peers
Gamida Cell Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
TERN | Terns Pharmaceuticals | 7.82 | ||||
HOOK | Hookipa Pharma | 6.90 | ||||
ARDX | Ardelyx | 6.36 | ||||
MCRB | Seres Therapeutics | 4.55 | ||||
BLRX | BioLineRx | 3.57 | ||||
IOVA | Iovance Biotherapeutics | 3.07 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
DAWN | Day One | 1.33 | ||||
PLX | Protalix Biotherapeutics | 0.60 | ||||
IBRX | Immunitybio | 0.39 | ||||
LXRX | Lexicon Pharmaceuticals | 2.44 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Gamida Stock
If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
Stocks Directory Find actively traded stocks across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |